Clinical trials: Itch
Tinea Pedis
A Therapeutic Equivalence Study of Ketoconazole Cream 2%
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
- Trial name
- NCT04203342
- Testing
- Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
- Where
- 3 sites in United States, Belize
- Volunteers
- 682 people
- Sponsor
- Douglas Pharmaceuticals America Ltd
Chronic Spontaneous Urticaria
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the…
- Trial name
- NCT05513001
- Testing
- LOU064 (blinded), LOU064 (open label)
- Where
- 208 sites in United States, Argentina and 28 more
- Volunteers
- 696 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
The objective of this 1 week trial is to evaluate the efficacy of an over-the-counter (OTC) 1% colloidal oatmeal skin protectant cream in adults and children with mild to moderate AD.
- Trial name
- NCT02691507
- Testing
- EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Vulvovaginal Candidiasis, Genital
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg…
- Trial name
- NCT06411314
- Testing
- Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories
- Where
- Russia
- Volunteers
- 218 people
- Sponsor
- Avva Rus, JSC
Pruritus
In-Use Test With a Cosmetic Product to Treat Pruritus
The aim of the study is to evaluate the cosmetic features of the product WO 3308 by means of a questionnaire in an interview situation after two weeks of product treatment, giving special consideration to the cosmetic…
- Trial name
- NCT03477058
- Testing
- WO 3308 cosmetic product for topical use
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Cholestatic Pruritus
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of twice-daily (BID) oral CR845 1.0 mg in patients with PBC with moderate-to-severe pruritus.
- Trial name
- NCT03995212
- Testing
- CR845 1.0 mg
- Where
- 14 sites in United States
- Volunteers
- 14 people
- Sponsor
- Cara Therapeutics, Inc.
Primary Biliary Cholangitis, PBC
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible…
- Trial name
- VANTAGE (NCT05050136)
- Testing
- Volixibat
- Where
- 130 sites in United States, Argentina and 13 more
- Volunteers
- 333 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell…
- Trial name
- NCT04333108
- Testing
- Masitinib, Best Supportive Care
- Where
- 17 sites in France, Germany and 6 more
- Volunteers
- 140 people
- Sponsor
- AB Science
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic…
- Trial name
- NCT07819071
- Testing
- Tested Emollient RV5258A, tacrolimus 0.1%
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Pruritus of the Scalp
In-Use Test of a Cosmetic Product in Subjects With Chronically Itchy Scalp
The aim of the study is to evaluate the tolerance of the Shampoo (WO 5101) on the scalp by a dermatologist and by the subjects themselves after four weeks of regular product use.
- Trial name
- NCT03630107
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Foot Fungus, Tinea
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
A prospective, open, post-market study that will enroll male and female subjects diagnosed with foot fungus and at least one of the following conditions: heel cracks, calluses and/or dry feet.
- Conditions
- Foot Fungus, Tinea, Tinea Pedis, Mycoses
- Trial name
- NCT04265521
- Testing
- Biocool Footcare
- Where
- 2 sites in Sweden
- Volunteers
- 25 people
- Sponsor
- Biocool AB
Atopic Dermatitis
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.
- Trial name
- NCT02651714
- Testing
- Tradipitant
- Where
- 28 sites in United States
- Volunteers
- 168 people
- Sponsor
- Vanda Pharmaceuticals
Prurigo Nodularis
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Participants were randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at…
- Trial name
- PRISM (NCT03497975)
- Testing
- Nalbuphine ER Tablets
- Where
- 70 sites in United States, Austria and 3 more
- Volunteers
- 353 people
- Sponsor
- Trevi Therapeutics
Atopic Dermatitis
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
- Trial name
- NCT03745651
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 66 sites in United States, Bulgaria and 5 more
- Volunteers
- 618 people
- Sponsor
- Incyte Corporation
Chronic Pruritus of Unknown Origin
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.
- Trial name
- CPUO (NCT07074977)
- Testing
- nemolizumab
- Where
- 26 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Uremic Pruritus
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
2 Part Study: Part A will assess 3 different dosing levels of IV CR845 versus placebo in patient on hemodialysis who have moderate-to-severe itching due to uremic pruritus.
- Trial name
- NCT02858726
- Testing
- CR845 0.5 mcg/kg, CR845 1 mcg/kg, CR845 1.5mcg/kg
- Where
- 29 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cara Therapeutics, Inc.
Tinea Pedis
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream…
- Trial name
- NCT01580891
- Testing
- Naftifine HCl Cream 1%, Naftin® (Naftifine HCl) Cream 1%
- Volunteers
- 1,053 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.